VolitionRX (NYSEAMERICAN:VNRX) Shares Cross Below Fifty Day Moving Average – Here’s Why

VolitionRX Limited (NYSEAMERICAN:VNRX)’s stock price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.76 and traded as low as $1.32. VolitionRX shares last traded at $1.39, with a volume of 228,591 shares changing hands.

Analyst Ratings Changes

A number of brokerages have issued reports on VNRX. Benchmark reissued a “hold” rating on shares of VolitionRX in a report on Tuesday, June 2nd. D. Boral Capital restated a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. Citigroup cut VolitionRX to a “hold” rating in a research report on Monday, April 20th. Finally, HC Wainwright cut their price objective on VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. One equities research analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $40.00.

VolitionRX Stock Up 2.2%

The firm has a market capitalization of $12.00 million, a PE ratio of -0.33 and a beta of 1.04. The stock has a 50-day moving average price of $2.76 and a 200 day moving average price of $4.25.

VolitionRX (NYSEAMERICAN:VNRX) last issued its quarterly earnings results on Thursday, May 14th. The medical research company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.27). The company had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.52 million. As a group, equities analysts predict that VolitionRX Limited will post -2.4 earnings per share for the current fiscal year.

Institutional Trading of VolitionRX

Several large investors have recently made changes to their positions in VNRX. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of VolitionRX during the second quarter worth approximately $52,000. Virtu Financial LLC purchased a new stake in shares of VolitionRX during the third quarter worth approximately $28,000. Citadel Advisors LLC increased its position in shares of VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after purchasing an additional 135,775 shares in the last quarter. Lagoda Investment Management L.P. increased its position in shares of VolitionRX by 6.7% during the third quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock worth $8,476,000 after purchasing an additional 782,000 shares in the last quarter. Finally, Armistice Capital LLC increased its position in shares of VolitionRX by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after purchasing an additional 887,351 shares in the last quarter. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.